clinical trial · NCT06724640
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
ViiV Healthcare·phase1·recruiting·n = 168
HIV InfectionsVH4011499 low dose InjectionVH4011499 high dose InjectionPlacebo
brief summary
The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.
started
Dec 16, 2024
primary completion
Aug 16, 2028
completion
Aug 16, 2028
last updated
Oct 29, 2025
official title
A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol